RGD Reference Report - Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.

Authors: Johansson, P  Aberg, D  Johansson, JO  Mattsson, N  Hansson, O  Ahren, B  Isgaard, J  Aberg, ND  Blennow, K  Zetterberg, H  Wallin, A  Svensson, J 
Citation: Johansson P, etal., Psychoneuroendocrinology. 2013 Sep;38(9):1729-37. doi: 10.1016/j.psyneuen.2013.02.006. Epub 2013 Mar 6.
RGD ID: 10402570
Pubmed: PMID:23473966   (View Abstract at PubMed)
DOI: DOI:10.1016/j.psyneuen.2013.02.006   (Journal Full-text)

BACKGROUND: Although insulin-like growth factor-I (IGF-I) is of importance for the adult function of the central nervous system (CNS), little is known of the significance of IGF-I in cerebrospinal fluid (CSF) in relation to Alzheimer's disease (AD). METHODS: A cross-sectional study of 60 consecutive patients under primary evaluation of cognitive impairment and 20 healthy controls. The patients had AD dementia or mild cognitive impairment (MCI) diagnosed with AD dementia upon follow-up (n=32), stable MCI (SMCI, n=13), or other dementias (n=15). IGF-I, IGF-binding protein-3 (IGFBP-3), and insulin were measured in serum and CSF. RESULTS: Serum IGF-I level was increased in AD patients and in patients with other dementias compared to healthy controls (P=0.01 and P<0.05, respectively). Serum IGFBP-3 concentration was increased in AD and SMCI patients compared to controls (P=0.001 and P<0.05, respectively). CSF levels of IGF-I and IGFBP-3 as well as serum and CSF levels of insulin were similar in all study groups. In the total study population (n=80), serum levels of IGF-I and IGFBP-3 correlated negatively with CSF beta-amyloid(1)(-)(4)(2) (Abeta(1)(-)(4)(2)) level (r=-0.29, P=0.01 and r=-0.27, P=0.02, respectively) and in the AD patients (n=32), the increased CSF/serum IGF-I ratio correlated positively with the CSF level of phosphorylated tau protein (P-tau; r=0.42, P=0.02). CONCLUSION: Patients with AD as well as other dementias had high levels of IGF-I in serum but not in CSF. In AD patients, the IGF-I system was associated with biomarkers of AD disease status.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Alzheimer's disease  IEP 10402570protein:increased expression:serumRGD 
Alzheimer's disease  ISOIGFBP3 (Homo sapiens)10402570; 10402570protein:increased expression:serumRGD 

Objects Annotated

Genes (Rattus norvegicus)
Igfbp3  (insulin-like growth factor binding protein 3)

Genes (Mus musculus)
Igfbp3  (insulin-like growth factor binding protein 3)

Genes (Homo sapiens)
IGFBP3  (insulin like growth factor binding protein 3)


Additional Information